Tuberculous uveitis: association between anti-tuberculous therapy and clinical response in a non-endemic country

Journal of Ophthalmic Inflammation and Infection

Table 2 Clinical presentation, treatment details, and clinical outcomes of 20 study patients

Case	Sex	Uveitis presentation	Unilateral or bilateral	Treatment regimen started	Duration therapy completed (months)	Additional systemic steroids	Uveitis improved
1	M	Panuveitis^a,b	Bilateral	RH^d	6	No	Yes
2	M	Posterior uveitis	Unilateral	RHZM	8	No	Yes
3	F	Panuveitis	Unilateral	RHZ	6	No	Yes
4	M	Anterior uveitis	Unilateral	RHZE	6	No	Yes^e
5	F	Panuveitis^a	Unilateral	RHZE	6	Yes	Yes
6	M	Anterior uveitis	Unilateral	–	–	No	Yes
7	F	Anterior uveitis	Bilateral	RHZE	18	Yes	No
8	M	Posterior uveitis^b,c	Bilateral	–	–	Yes	No
9	M	Panuveitis	Unilateral	RHZE	9	Yes	Yes
10	M	Anterior uveitis^c	Bilateral	RHZE	6	Yes	Yes
11	F	Panuveitis^a,b	Bilateral	RHZE	6	Yes	Yes
12	M	Posterior uveitis^b	Unilateral	RHZM	5	Yes	Yes
13	F	Anterior, intermediate uveitis^a	Bilateral	RHZM	9	No	Yes
14	F	Anterior, intermediate uveitis^a	Bilateral	RHZM	6	No	Yes
15	F	Panuveitis^a,c	Bilateral	RHZE	Sporadic	Yes	No
16	M	Anterior, intermediate uveitis^b	Bilateral	–	–	Yes	No
17	M	Anterior uveitis^a	Unilateral	RHZE	7	No	Yes
18	F	Anterior uveitis	Unilateral	RPTH	3	Yes	No
19	M	Panuveitis uveitis	Bilateral	RHZE	6	Yes	Yes
20	M	Panuveitis	Bilateral	RHZL	7	Yes	Yes

^aCases born in a high TB-burden country: 1, 5, 11, 13, 14, 15, 17
^bCases with underlying immunosuppression: 1, 8, 11, 12, 16
^cCases with reported prior active TB: 8, 10, 15
^dATT abbreviations: R—rifampin, RPT—rifapentine, H—isoniazid, Z—pyrazinamide, E—ethambutol, M—moxifloxacin
^eInflammation improved before the start of ATT